Equities
Health CarePharmaceuticals and Biotechnology
  • Price (MXN)6,485.65
  • Today's Change-126.35 / -1.91%
  • Shares traded45.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 19 2024 20:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Income statement Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
REVENUE AND GROSS PROFIT
Total revenue28,19026,32325,979
OPERATING EXPENSES
Cost of revenue total8,4156,4066,454
Selling, general and admin. expenses, total6,1665,4145,368
Depreciation/amortization------
Unusual expense(income)424891,505
Other operating expenses, total690(64)194
Total operating expense20,06816,67918,340
Operating income8,1229,6447,639
Other, net2,370(892)259
INCOME TAXES, MINORITY INTEREST AND EXTRA ITEMS
Net income before taxes7,8557,3466,701
Provision for income taxes1,138794808
Net income after taxes6,7176,5525,893
Minority interest------
Net income before extra. Items6,7176,5525,893
Total extraordinary items------
Net income6,7176,5525,893
Inc.avail. to common excl. extra. Items6,7176,5525,893
Inc.avail. to common incl. extra. Items6,7176,5525,893
EPS RECONCILIATION
Basic/primary weighted average shares535538570
Basic/primary eps excl. extra items131210
Basic/primary eps incl. extra items131210
Dilution adjustment------
Diluted weighted average shares538541573
Diluted eps excl. extra items121210
Diluted eps incl. extra items121210
COMMON STOCK DIVIDENDS
DPS - common stock primary issue8.527.767.04
Gross dividend - common stock4,6444,2644,098
PRO FORMA INCOME
Pro forma net income------
Interest expense, supplemental2,8751,4061,197
SUPPLEMENTAL INCOME
Depreciation, supplemental871817798
Total special items424891,505
NORMALISED INCOME
Normalized income before taxes7,8977,8358,206
Effect of special items on income taxes6.08530
Income tax excluding impact of special items1,144847808
Normalized income after tax6,7536,9887,398
Normalized income avail. to common6,7536,9887,398
Basic normalized EPS131313
Diluted normalized EPS131313
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.